CHALFONT ST. GILES, UK and BEIJING, CHINA – 18 September 2018 – BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has selected GE Healthcare Life Sciences’ off-the-shelf biomanufacturing facility, KUBio for large-scale production of its cancer monoclonal antibodies (mAbs).
http://www.genewsroom.com/press-releases/beigene-selects-ge-healthcare%E2%80%99s-shelf-biologics-factory-boost-its-manufacturing